Apollomics is focused on the discovery and development of oncology mono- and combination-therapies. The company’s lead programs include APL-101, an orally administered selective c-MET inhibitor, and APL-106 (uproleselan), a targeted E-selectin antagonist that has received FDA Breakthrough Therapy Designation in relapsed and refractory acute myeloid leukemia. APL-101 is enrolling the Phase 2 portion of the international SPARTA trial, and Apollomics is planning a Phase 1 PK study and a Phase 3 bridging trial in China for APL-106. Since founding in 2016 and incubated by OrbiMed Asia at inception, Apollomics has advanced six assets across more than ten clinical trials in the U.S. and China. The company pursues a precision-medicine approach targeting specific mutations, amplifications, and resistance mechanisms to develop single-agent and combination regimens. The recently completed Series C financing will support progression of the pipeline and expansion of programs globally. Apollomics is an innovative biopharmaceutical company focused on discovering and developing oncology combination therapies that harness the immune system and target molecular pathways. Its pipeline includes six development-stage assets: three novel humanized monoclonal antibodies designed to restore immune recognition of cancer cells, and three targeted therapies against uncontrolled growth signaling pathways. The company plans to use new funding to accelerate growth by advancing multiple oncology programs, exploring new treatment areas, increasing its pipeline of assets, and expanding talent and infrastructure. Apollomics was incubated by OrbiMed Asia and is led by CEO Guo-Liang Yu, PhD, and President Sanjeev Redkar, PhD. Formerly CBT Pharmaceuticals, the company is based in Foster City, California and in 2018 established a presence in Hangzhou, China to build R&D and manufacturing capabilities. CBT Pharmaceuticals is advancing a pipeline of oncology therapeutics consisting of four development-stage assets. Core programs include CBT-101, an oral c-Met inhibitor targeting the EMT pathway, and CBT-501, a humanized anti–PD-1 monoclonal antibody; the pipeline also contains a pre-clinical multi-targeted kinase inhibitor and a PD-L1 antibody. The company plans to advance two of its four programs into human clinical trials. CBT-101 is in a Phase 1 trial in China and a U.S. Phase 1 was planned for early 2017; CBT-501 has an IND filed and is awaiting Phase 1 starts in China with plans for trials in southeast Asia in 2017. The company was founded in 2016 and is headquartered in California. Management was expanded with the addition of Gavin Choy as Executive VP and COO to oversee ongoing clinical development.

Total raised

$234M

Funding rounds

3

Latest round

Series C

Latest activity

Nov 2020